Biomarker ID 2502 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2502 |
| Biomarker | CAPG, OCC-1, EED, RPLP0, RPLP0P2, AP1S2, RRAGD, PFDN4, CCDC104, C7orf28B, PSIP1, LPCAT1, FSCN3, RAB24, ZNF446, SEC11B, ZNF586, SCNM1, SF3A1, RUFY1, TRIM55, GOLGA4, GPATCH4, THOP1, TUBB2C, PHLDB3, FAM104A, FASTK, EIF2AK4, ZFP41, PRKRIP1, DSTN, PHIP, NUCKS1, TNRC8, CCDC132, EPRS, HIST1H4C, CDCA8, |
| Biomarker Name/Symbol (given in Publication) | 40 genes-signature (CAPG, OCC-1, EED, RPLP0, RPLP0P2, AP1S2, RRAGD, PFDN4, CCDC104, C7orf28B, PSIP1, LPCAT1, FSCN3, RAB24, ZNF446, SEC11B, ZNF586, SCNM1, SF3A1, RUFY1, TRIM55, GOLGA4, GPATCH4, THOP1, TUBB2C, PHLDB3, FAM104A, FASTK, EIF2AK4, ZFP41, PRKRIP1, DSTN, PHIP, NUCKS1, TNRC8, CCDC132, EPRS, HIST1H4C, CDCA8) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential biomarkers for diagnosis of HCV-related HCC; but not validated on independent dataset |
| Experimental Condition | HCV related HCC v/s HCV related non-HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCV related HCC than HCV related non-HCC (With 3-fold change) |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 19821982 |
| Type of Biomarker | Diagnostic |
| Pathway | Metabolism, Aryl Hydrocarbon receptor signaling, 14-3-3 mediated signaling and protein Ubiquitination pathways. |
| Cohort | 14 HCV-related HCC and non-HCC counterpart, as well as 7 HCV-negative control patients |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV-associated HCC |
| Year of Publication | 2009 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |